{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:55:09Z","timestamp":1792716909438,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ad.2026.104632","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:37:09Z","timestamp":1773941829000},"page":"104632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patient- and Clinician-reported Outcomes, Safety and Efficacy Profile of Tirbanibulin 1% for Actinic Keratosis Under Conditions Close to Routine Clinical Practice in Spain and Italy (TIRBASKIN Study)"],"prefix":"10.1016","volume":"117","author":[{"given":"Y.","family":"Gilaberte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Y\u00e9lamos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ca\u00f1ueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Serra-Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pajuelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Cappello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kostov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Padull\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2026.104632_bib0155","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ad.2016.05.016","article-title":"Prevalence of actinic keratosis among dermatology outpatients in Spain","volume":"107","author":"Ferr\u00e1ndiz","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2026.104632_bib0160","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/bjd\/ljad371","article-title":"Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis","volume":"190","author":"George","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2026.104632_bib0165","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/jdv.19897","volume":"38","author":"Kandolf","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2026.104632_bib0170","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2147\/CCID.S374122","article-title":"Tirbanibulin for actinic keratosis: insights into the mechanism of action","volume":"15","author":"Schlesinger","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.ad.2026.104632_bib0175","series-title":"Klisyri \u2013 Summary of Product Characteristics","year":"2024"},{"key":"10.1016\/j.ad.2026.104632_bib0180","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.36849\/JDD.2020.5576","article-title":"Tirbanibulin ointment 1% as a novel treatment for actinic keratosis: phase 1 and 2 results","volume":"19","author":"Kempers","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2026.104632_bib0185","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/10600280211031329","article-title":"1% tirbanibulin ointment for the treatment of actinic keratoses","volume":"56","author":"Dao","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ad.2026.104632_bib0190","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1056\/NEJMoa2024040","article-title":"Phase 3 trials of tirbanibulin ointment for actinic keratosis","volume":"384","author":"Blauvelt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2026.104632_bib0195","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/cpdd.1368","article-title":"Pharmacokinetics, safety, and tolerability of a single 5-day treatment of tirbanibulin ointment 1% in 100cm2: a phase 1 maximal-use trial in patients with actinic keratosis","volume":"13","author":"DuBois","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ad.2026.104632_bib0200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jdin.2024.07.001","article-title":"Safety and tolerability of tirbanibulin ointment 1% treatment on 100cm2 of the face or scalp in patients with actinic keratosis: a phase 3 study","volume":"17","author":"Bhatia","year":"2024","journal-title":"JAAD Int"},{"key":"10.1016\/j.ad.2026.104632_bib0205","doi-asserted-by":"crossref","first-page":"771","DOI":"10.25251\/skin.7.3.3","article-title":"Clinician- and patient-reported outcomes with tirbanibulin 1% treatment for actinic keratosis in routine clinical practice across the U.S. (PROAK study)","volume":"7","author":"Schlesinger","year":"2023","journal-title":"SKIN J Cutan Med"},{"key":"10.1016\/j.ad.2026.104632_bib0210","doi-asserted-by":"crossref","first-page":"338","DOI":"10.36849\/JDD.8264","article-title":"Patient- and clinician-reported outcomes for tirbanibulin in actinic keratosis in clinical practice across the United States (PROAK)","volume":"23","author":"Schlesinger","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2026.104632_bib0215","series-title":"Real-world evidence of tirbanibulin for actinic keratosis in Germany. Insights into patient-reported outcomes, safety and effectiveness (Abstract 1571). Amsterdam, The Netherlands","author":"Heppt","year":"2024"},{"key":"10.1016\/j.ad.2026.104632_bib0220","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ad.2026.104632_bib0225","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/120347540100500202","article-title":"Measurement properties of skindex-16: a brief quality-of-life measure for patients with skin diseases","volume":"5","author":"Chren","year":"2001","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2026.104632_bib0230","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.jid.5700740","article-title":"Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"127","author":"Chren","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2026.104632_bib0235","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ad.2026.104632_bib0240","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jdin.2023.09.006","article-title":"Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: results from an expert panel","volume":"16","author":"Berman","year":"2024","journal-title":"JAAD Int"},{"key":"10.1016\/j.ad.2026.104632_bib0245","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3390\/jcm11061654","article-title":"Comparative efficacy and safety of tirbanibulin for actinic keratosis of the face and scalp in Europe: a systematic review and network meta-analysis of randomized controlled trials","volume":"11","author":"Heppt","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ad.2026.104632_bib0250","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/CCID.S121323","article-title":"Patient satisfaction and reported outcomes on the management of actinic keratosis","volume":"10","author":"Khanna","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.ad.2026.104632_bib0255","first-page":"1362","article-title":"If patients had a choice \u2013 treatment satisfaction and patients\u2019 preference in therapy of actinic keratoses","volume":"22","author":"Lang","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ad.2026.104632_bib0260","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14833","article-title":"Patient-reported outcomes of topical therapies in actinic keratosis: a systematic review","volume":"34","author":"Grada","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2026.104632_bib0265","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/09546634.2017.1329514","article-title":"Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients","volume":"29","author":"Norrlid","year":"2018","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2026.104632_bib0270","article-title":"Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome","volume":"8","author":"Ezzedine","year":"2020","journal-title":"J Mark Access Health Policy"},{"key":"10.1016\/j.ad.2026.104632_bib0275","first-page":"1218","article-title":"Efficacy, safety, and tolerability of 4% 5-fluorouracil cream in a novel patented aqueous cream containing peanut oil once daily compared with 5% 5-fluorouracil cream twice daily: meeting the challenge in the treatment of actinic keratosis","volume":"15","author":"Dohil","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2026.104632_bib0280","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/ijd.17168","article-title":"Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients","volume":"63","author":"Nazzaro","year":"2024","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2026.104632_bib0285","article-title":"Real-world experience with topical 5-fluorouracil 4% (40mg\/g) cream for the treatment of actinic keratosis","volume":"13","author":"Briatico","year":"2023","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.ad.2026.104632_bib0290","doi-asserted-by":"crossref","DOI":"10.23736\/S2784-8671.21.07111-5","article-title":"Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care","volume":"157","author":"Perino","year":"2022","journal-title":"Ital J Dermatol Venereol"},{"key":"10.1016\/j.ad.2026.104632_bib0295","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13555-024-01336-4","article-title":"Association between local skin reactions and efficacy with 5-fluorouracil 4% cream in actinic keratosis: a post-hoc analysis of two randomised clinical trials","volume":"15","author":"Heppt","year":"2025","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ad.2026.104632_bib0300","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3390\/ph16121686","article-title":"Preliminary evidence of efficacy, safety, and treatment satisfaction with tirbanibulin 1% ointment: a clinical perspective on actinic keratoses","volume":"16","author":"Campione","year":"2023","journal-title":"Pharmaceuticals"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731026000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731026000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:16:24Z","timestamp":1782926184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731026000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0001731026000426"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2026.104632","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient- and Clinician-reported Outcomes, Safety and Efficacy Profile of Tirbanibulin 1% for Actinic Keratosis Under Conditions Close to Routine Clinical Practice in Spain and Italy (TIRBASKIN Study)","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2026.104632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104632"}}